Floatz logo

HAFNIUM OXIDE

Metastatic Malignant Neoplasm in the Lung

M.D. Anderson Cancer CenterOtherPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Metastatic Malignant Neoplasm in the Lung cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Roswell Park Cancer Institute
Phase 1/2B
Indocyanine Green
M.D. Anderson Cancer Center
Phase 2CCC
Cediranib
Roswell Park Cancer Institute
Phase 1CC
Iopamidol
Stanford University
Phase 1CC
Nivolumab
Mayo Clinic
Phase 1CC
Sargramostim
Mayo Clinic
Phase 1CC
18f-αvβ6-bp
Julie L. Sutcliffe, Ph.D
Early Phase 1C
Doxepin
Mayo Clinic
Phase 2C

Same molecule, other indications

HAFNIUM OXIDE is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →
Advanced Malignant Solid NeoplasmDormant
CC
Indicative ·
45 / 100
View asset →
Metastatic Malignant Neoplasm in the LiverDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →